top of page
DSC04595.jpg

PUBLICATIONS

2024

Stamouli CA, Degener A, Cepeda-Prado E, Bruzelius A, Andersson E, Giacomoni J, Vorgeat AD, Kidnapillai S, Klementieva O, Parmar M, Olariu V, Rylander Ottosson D. Generating human parvalbumin interneurons through 3D glia reprogramming. bioRxiv. 2024:2024.09.06.609855. doi: 10.1101/2024.09.06.609855.

​

Giacomoni J, Bruzelius A, Habekost M, Kajtez J, Ottosson DR, Fiorenzano A, Storm P, Parmar M. 3D model for human glia conversion into subtype-specific neurons, including dopamine neurons. Cell Rep Methods. 2024 Aug 27:100845.  Epub ahead of print. PMID: 39236715. doi: 10.1016/j.crmeth.2024.100845.

​

2023

Gvazava N, Konings SC, Cepeda-Prado E, Skoryk V, Umeano CH, Dong J, Silva IAN, Ottosson DR, Leigh ND, Wagner DE et al. Label-free high-resolution photothermal optical infrared spectroscopy for spatiotemporal chemical analysis in fresh, hydrated living tissues and embryos. Journal of the American Chemical Society. 2023 Nov. doi: ​10.1021/jacs.3c08854

​

​Ottosson DR, Pereira CF. Reprogramming Stars #13: Establishing Connections with Cellular Reprogramming-An Interview with Dr. Daniella Rylander Ottosson. Cell Reprogram. 2023 Aug;25(4):130-135. doi: 10.1089/cell.2023.0078.

 

Canals I, Comella-Bolla A, Cepeda-Prado E, Avaliani N, Crowe JA, Oburoglu L, Bruzelius A, King N, Pajares MA, Pérez-Sala D, Heuer A, Rylander Ottosson D, Soriano J, Ahlenius H. Astrocyte dysfunction and neuronal network hyperactivity in a CRISPR engineered pluripotent stem cell model of frontotemporal dementia. Brain Communications. 2023. doi: 10.1093/braincomms/fcad158.

​

Giacomoni J, Habekost M, Cepeda-Prado E, Mattsson B, Ottosson DR, Parmar M, Kajtez J. Protocol for optical clearing and imaging of fluorescently labeled ex vivo rat brain slices. STAR Protoc. 2023 Jan 18;4(1):102041. doi: 10.1016/j.xpro.2022.102041.

 

2022

Sozzi E, Kajtez J, Bruzelius A, Wesseler MF, Nilsson F, Birtele M, Larsen NB, Ottosson DR, Storm P, Parmar M, Fiorenzano A. Silk scaffolding drives self-assembly of functional and mature human brain organoids. Front Cell Dev Biol. 2022 Oct 14;10:1023279. doi: 10.3389/fcell.2022.1023279. 

​

Birtele M, Storm P, Sharma Y, Kajtez J, Wahlestedt JN, Sozzi E, Nilsson F, Stott S, He XL, Mattsson B, Ottosson DR, Barker RA, Fiorenzano A, Parmar M. Single-cell transcriptional and functional analysis of dopaminergic neurons in organoid-like cultures derived from human fetal midbrain. Development. 2022 Oct 28:dev.200504. doi: 10.1242/dev.200504.

​

Drouin-Ouellet J, Legault EM, Nilsson F, Pircs K, Bouquety J, Petit F, Shrigley S, Birtele M, Pereira M, Storm P, Sharma Y, Bruzelius A, Vuono R, Kele M, Stoker TB, Ottosson DR, Falk A, Jakobsson J, Barker RA, Parmar M. Age-related pathological impairments in directly reprogrammed dopaminergic neurons derived from patients with idiopathic Parkinson's disease. Stem Cell Reports. 2022 Oct 11;17(10):2203-2219. doi: 10.1016/j.stemcr.2022.08.010. 

​

Kajtez J, Wesseler MF, Birtele M, Khorasgani FR, Rylander Ottosson D, Heiskanen A, Kamperman T, Leijten J, Martínez-Serrano A, Larsen NB, Angelini TE, Parmar M, Lind JU, Emnéus J. Embedded 3D Printing in Self-Healing Annealable Composites for Precise Patterning of Functionally Mature Human Neural Constructs. Adv Sci (Weinh). 2022 Sep;9(25):e2201392. doi: 10.1002/advs.202201392. 

​

2021

Fiorenzano A, Sozzi E, Birtele M, Kajtez J, Giacomoni J, Nilsson F, Bruzelius A, Sharma Y, Zhang Y, Mattsson B, Emnéus J, Ottosson DR, Storm P, Parmar M. Single-cell transcriptomics captures features of human midbrain development and dopamine neuron diversity in brain organoids. Nat Commun. 2021 Dec 15;12(1):7302. doi: 10.1038/s41467-021-27464-5. 

 

Bruzelius A, Kidnapillai S, Drouin-Ouellet J, Stoker T, Barker RA, Rylander Ottosson D. Reprogramming Human Adult Fibroblasts into GABAergic Interneurons. Cells. 2021; 10(12):3450. https://doi.org/10.3390/cells10123450

​

Kidnapillai S, Ottosson DR. Functional Assessment of Direct Reprogrammed Neurons In Vitro and In Vivo. Methods Mol Biol. 2021;2352:183-199. doi: 10.1007/978-1-0716-1601-7_13.

Rylander Ottosson D, Grade S and Heuer A. Editorial: Regeneration and Brain Repair. Front. Cell. Neurosci.2021;15:687992.

doi: 10.3389/fncel.2021.687992

​

2020

Shrigley S, Nilsson F, Mattsson B, Fiorenzano A, Mudannayake J, Bruzelius A, Ottosson DR, Björklund A, Hoban DB, Parmar M. Grafts Derived from an α-Synuclein Triplication Patient Mediate Functional Recovery but Develop Disease-Associated Pathology in the 6-OHDA
Model of Parkinson’s Disease. Journal of Parkinson's Disease, 2020 Preprint:1-14. doi:10.3233/JPD-202366

Giacomoni J, Bruzelius A, Stamouli CA, Rylander Ottosson D. Direct Conversion of Human Stem Cell-Derived Glial Progenitor Cells into GABAergic Interneurons. Cells. 2020;9(11):2451. Published 2020 Nov 10. doi:10.3390/cells9112451

Nolbrant S, Giacomoni J, Hoban DB, et al. Direct Reprogramming of Human Fetal- and Stem Cell-Derived Glial Progenitor Cells into Midbrain Dopaminergic Neurons. Stem Cell Reports. 2020;15(4):869-882. doi:10.1016/j.stemcr.2020.08.013

2019

Pereira M, Birtele M, Rylander Ottosson D. In Vivo Direct Reprogramming of Resident Glial Cells into Interneurons by Intracerebral Injection of Viral Vectors. J Vis Exp. 2019;(148):10.3791/59465. Published 2019 Jun 17. doi:10.3791/59465

Pereira M, Birtele M, Rylander Ottosson D. Direct reprogramming into interneurons: potential for brain repair. Cell Mol Life Sci. 2019;76(20):3953-3967. doi:10.1007/s00018-019-03193-3

Birtele M, Sharma Y, Kidnapillai S, et al. Dual modulation of neuron-specific microRNAs and the REST complex promotes functional maturation of human adult induced neurons. FEBS Lett. 2019;593(23):3370-3380. doi:10.1002/1873-3468.13612

2018

Pereira M, Birtele M, Shrigley S, Benitez JA, Hedlund E, Parmar M, Ottosson DR. Direct Reprogramming of Resident NG2 Glia into Neurons with Properties of Fast-Spiking Parvalbumin-Containing Interneurons. Stem Cell Reports. 2017 Sep 12;9(3):742-751. doi: 10.1016/j.stemcr.2017.07.023. 

Ruetz T, Pfisterer U, Di Stefano B, et al. Constitutively Active SMAD2/3 Are Broad-Scope Potentiators of Transcription-Factor-Mediated Cellular Reprogramming. Cell Stem Cell. 2017;21(6):791-805.e9. doi:10.1016/j.stem.2017.10.013

Drouin-Ouellet J, Lau S, Brattås PL, et al. REST suppression mediates neural conversion of adult human fibroblasts via microRNA-dependent and -independent pathways. EMBO Mol Med. 2017;9(8):1117-1131. doi:10.15252/emmm.201607471

Kirkeby A, Nolbrant S, Tiklova K, et al. Predictive Markers Guide Differentiation to Improve Graft Outcome in Clinical Translation of hESC-Based Therapy for Parkinson's Disease. Cell Stem Cell. 2017;20(1):135-148. doi:10.1016/j.stem.2016.09.004

2015

Torper O, Ottosson DR, Pereira M, et al. In Vivo Reprogramming of Striatal NG2 Glia into Functional Neurons that Integrate into Local Host Circuitry. Cell Rep. 2015;12(3):474-481. doi:10.1016/j.celrep.2015.06.040

2014

Lau S, Rylander Ottosson D, Jakobsson J, Parmar M. Direct neural conversion from human fibroblasts using self-regulating and nonintegrating viral vectors. Cell Rep. 2014;9(5):1673-1680. doi:10.1016/j.celrep.2014.11.017

Pereira M, Pfisterer U, Rylander D, et al. Highly efficient generation of induced neurons from human fibroblasts that survive transplantation into the adult rat brain. Sci Rep. 2014;4:6330. Published 2014 Sep 11. doi:10.1038/srep06330

2013

Rylander D, Bagetta V, Pendolino V, et al. Region-specific restoration of striatal synaptic plasticity by dopamine grafts in experimental parkinsonism. Proc Natl Acad Sci U S A. 2013;110(46):E4375-E4384. doi:10.1073/pnas.1311187110

Iderberg H, Rylander D, Bimpisidis Z, Cenci MA. Modulating mGluR5 and 5-HT1A/1B receptors to treat l-DOPA-induced dyskinesia: effects of combined treatment and possible mechanisms of action. Exp Neurol. 2013;250:116-124. doi:10.1016/j.expneurol.2013.09.003

2011

Lindgren HS, Rylander D, Iderberg H, et al. Putaminal upregulation of FosB/ΔFosB-like immunoreactivity in Parkinson's disease patients with dyskinesia. J Parkinsons Dis. 2011;1(4):347-357. doi:10.3233/JPD-2011-11068

2010

Rylander D, Parent M, O'Sullivan SS, et al. Maladaptive plasticity of serotonin axon terminals in levodopa-induced dyskinesia. Ann Neurol. 2010;68(5):619-628. doi:10.1002/ana.22097

Rylander D, Iderberg H, Li Q, et al. A mGluR5 antagonist under clinical development improves L-DOPA-induced dyskinesia in parkinsonian rats and monkeys. Neurobiol Dis. 2010;39(3):352-361. doi:10.1016/j.nbd.2010.05.001

Malmlöf T, Rylander D, Alken RG, et al. Deuterium substitutions in the L-DOPA molecule improve its anti-akinetic potency without increasing dyskinesias. Exp Neurol. 2010;225(2):408-415. doi:10.1016/j.expneurol.2010.07.018

2009

Schuster S, Doudnikoff E, Rylander D, et al. Antagonizing L-type Ca2+ channel reduces development of abnormal involuntary movement in the rat model of L-3,4-dihydroxyphenylalanine-induced dyskinesia. Biol Psychiatry. 2009;65(6):518-526. doi:10.1016/j.biopsych.2008.09.008

Rylander D, Recchia A, Mela F, Dekundy A, Danysz W, Cenci MA. Pharmacological modulation of glutamate transmission in a rat model of L-DOPA-induced dyskinesia: effects on motor behavior and striatal nuclear signaling. J Pharmacol Exp Ther. 2009;330(1):227-235. doi:10.1124/jpet.108.150425

2007

Lindgren HS, Rylander D, Ohlin KE, Lundblad M, Cenci MA. The "motor complication syndrome" in rats with 6-OHDA lesions treated chronically with L-DOPA: relation to dose and route of administration. Behav Brain Res. 2007;177(1):150-159. doi:10.1016/j.bbr.2006.09.019

bottom of page